skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Review

(2228) Views  (718) Full article downloads

Authors: Anne J Lee, Peter McCluskey

Published Date July 2010 Volume 2010:4 Pages 741 - 764
DOI: http://dx.doi.org/10.2147/OPTH.S10441

Anne J Lee1,2, Peter McCluskey2,3

1Manchester Royal Eye Hospital, Manchester, UK; 2University of Sydney, Sydney, Australia; 3Sydney Eye Hospital, Sydney, Australia

Abstract: Prostaglandin analogs (PGA) are powerful topical ocular hypotensive agents available for the treatment of elevated intraocular pressure (IOP). Latanoprost 0.005% and travoprost 0.004% are prodrugs and analogs of prostaglandin F2a. Bimatoprost 0.03% is regarded as a prostamide, and debate continues as to whether it is a prodrug. The free acids of all 3 PGAs reduce IOP by enhancing uveoscleral and trabecular outflow via direct effects on ciliary muscle relaxation and remodeling of extracellular matrix. The vast majority of clinical trials demonstrate IOP-lowering superiority of latanoprost, bimatoprost and travoprost compared with timolol 0.5%, brimonidine 0.2%, or dorzolamide 2% monotherapy. Bimatoprost appears to be more efficacious in IOP-lowering compared with latanoprost, with weighted mean difference in IOP reduction documented in one meta-analysis of 2.59% to 5.60% from 1- to 6-months study duration. PGAs reduce IOP further when used as adjunctive therapy. Fixed combinations of latanoprost, bimatoprost or travoprost formulated with timolol 0.5% and administered once daily are superior to monotherapy of its constituent parts. PGA have near absence of systemic side effects, although do have other commonly encountered ocular adverse effects. The adverse effects of PGA, and also those found more frequently with bimatoprost use include ocular hyperemia, eyelash growth, and peri-ocular pigmentary changes. Iris pigmentary change is unique to PGA treatment. Once daily administration and near absence of systemic side effects enhances tolerance and compliance. PGAs are often prescribed as first-line treatment for ocular hypertension and open-angle glaucoma.

Keywords: prostaglandin analog, glaucoma, ocular hypertension, latanoprost, bimatoprost, travoprost







Readers of this article also read:

Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
New approach for the glaucoma detection with pupil perimetry
Measuring accurate IOPs: Does correction factor help or hurt?
Measurement of treatment compliance using a medical device for glaucoma patients associated with intraocular pressure control: a survey
Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations
Erratum
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum
Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from ß-blockers and prostaglandin analogs